Human Anti-CD45RB Antibody Product Attributes
CD45RB Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in CD45RB antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in lymphoid tissue in appendix, hematopoietic cells in the bone marrow, germinal center cells in the lymph node, non-germinal center cells in the lymph node, cells in the red pulp in spleen, cells in the white pulp in spleen, germinal center cells in the tonsil and non-germinal center cells in the tonsil. More moderate antibody staining intensity was present in lymphoid tissue in appendix, hematopoietic cells in the bone marrow, germinal center cells in the lymph node, non-germinal center cells in the lymph node, cells in the red pulp in spleen, cells in the white pulp in spleen, germinal center cells in the tonsil and non-germinal center cells in the tonsil. Low, but measureable presence of CD45RB could be seen in. We were unable to detect CD45RB in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD45RB expression as measured by anti-CD45RB antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | +++ | – | – | – | – | – | – | – | – | – | – |
| PTPRC Variability | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| CD45RB General Information | |
|---|---|
| Alternate Names | |
| Protein tyrosine phosphatase, receptor type, C, PTPRC | |
| Molecular Weight | |
| 180-220kDa | |
| Chromosomal Location | |
| 1q31.3 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | PTPRC |
| Entrez Gene ID | 5788 |
| Ensemble Gene ID | ENSG00000081237, ENSG00000262418 |
| RefSeq Protein Accession(s) | XP_006711537, XP_006711536, XP_006711535, NP_563578, NP_001254727, NP_002829 |
| RefSeq mRNA Accession(s) | XM_006711473, XM_006711474, NM_080921, NM_080922, NM_001267798, NM_002838, XM_006711472, NR_052021 |
| RefSeq Genomic Accession(s) | NG_007730, NC_000001, NW_003315907, NC_018912 |
| UniProt ID(s) | X6R433, A0A0A0MT22, P08575, M9MML4 |
| UniGene ID(s) | X6R433, A0A0A0MT22, P08575, M9MML4 |
| HGNC ID(s) | 9666 |
| Cosmic ID(s) | PTPRC |
| KEGG Gene ID(s) | hsa:5788 |
| PharmGKB ID(s) | PA34011 |
| General Description of CD45RB. | |
| CD45R, also designated CD45 and PTPRC, has been identified as a transmembrane glycoprotein, broadly expressed among hematopoietic cells. Multiple isoforms of CD45R are distributed throughout the immune system according to cell type. These isoforms arise because of alternative splicing of exons 4, 5, and 6. The corresponding protein domains are characterized by the binding of monoclonal antibodies specific for CD45RA (exon 4), CD45RB (exon 5), CD45RC (exon 6) and CD45RO (exons 4 to 6 spliced out). The variation in these isoforms is localized to the extracellular domain of CD45R, while the intracellular domain is conserved. CD45RB is expressed on mature B-lymphocytes and the majority of lymphomas and leukemias of B-cell origin. | |
There are no reviews yet.